Galapagos NV
AEX:LKFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Galapagos NV
AEX:LKFT
|
BE |
|
Novartis AG
F:NOT
|
CH |
|
L
|
Lam Research Corp
DUS:LAR
|
US |
|
Infineon Technologies AG
F:IFX
|
DE |
|
A
|
Angi Inc
F:2UH
|
US |
|
C
|
Comtech Telecommunications Corp
SWB:CC6
|
US |
|
W
|
Wilmar International Ltd
F:RTH
|
SG |
|
Ceconomy AG
F:MEOD
|
DE |
|
S
|
SISB PCL
SET:SISB
|
TH |
|
E
|
El Pollo Loco Holdings Inc
SWB:EP6
|
US |
|
K
|
Koppers Holdings Inc
F:KO9
|
US |
|
C
|
CME Group Inc
SWB:MX4A
|
US |
|
Thales SA
F:CSF0
|
FR |
|
Sasol Ltd
NYSE:SSL
|
ZA |
|
Henkel AG & Co KGaA
F:HEN3
|
DE |
|
Societe de Services de Participations, de Direction et d'Elaboration SA
XBRU:SPA
|
BE |
|
Tri Banyan Tirta Tbk PT
IDX:ALTO
|
ID |
|
I
|
ITV PLC
XBER:IJ7
|
UK |
|
M
|
Manhattan Associates Inc
F:MHT
|
US |
Bankruptcy Probability
Galapagos NV's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Galapagos NV Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| BE |
|
Galapagos NV
AEX:GLPG
|
1.6B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
379.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
67.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.7B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
40.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Galapagos NV's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Galapagos NV has total debt of 5.2m EUR. This includes both short-term (0 EUR) and long-term (5.2m EUR) debt.
You can find a full breakdown on its Balance Sheet.
